Strict regulation of T cell function is imperative to control adaptive immunity, and dysregulation of T cell activation can contribute to infectious and autoimmune diseases. Vasoactive intestinal peptide receptor-1 (VPAC-1), an anti-inflammatory G-protein coupled receptor, has been reported to be downregulated during T cell activation. However, the regulatory mechanisms controlling the expression of VPAC-1 in T cells are not well understood. Therefore, mouse splenic CD4 T cells were treated in complete media ± anti-CD3 for 24 h, total RNA isolated and VPAC-1 levels measured by qPCR. Surprisingly, we discovered that T cells incubated in complete media steadily upregulated VPAC-1 mRNA levels over time (24 h). Importantly, CD4 T cells isolated from blood also showed elevated VPAC-1 expression compared to splenic T cells. Collectively, these data support that the vascular environment positively influences VPAC-1 mRNA expression that is negatively regulated by TCR signaling.
Introduction
Vasoactive intestinal peptide (VIP) is a 28 amino acid (AA) molecule that performs crucial biological activities, including immunological protection (Nussdorfer and Malendowicz, 1998) . VIP is part of the glucagon/PACAP/secretin (GPS) superfamily that consists of nine small peptides, which share similar but distinct biological roles (Dorsam et al., 2000) . VIP binds two structurally similar receptors that share %50% AA homology called vasoactive intestinal peptide receptor-1 (VPAC-1) and VPAC-2. VIP receptors belong to the GPS class IIA, seven transmembrane, G-protein coupled receptor (GPCR) superfamily and are encoded by separate genes. VIP and PACAP (Pituitary adenylyl cyclase-activating polypeptide) binding evokes three major signaling pathways: G s /cAMP/PKA, G q /PLC/Ca 2+ and PLD activation (O'Dorisio et al., 1981; Delporte et al., 1995; Xia et al., 1996; McCulloch et al., 2000 , reviewed by Goetzl et al., 1995 . Both peptide ligands modulate numerous T cell functions including, proliferation (Ottaway and Greenberg, 1984; Wang et al., 2000) , trafficking (Ottaway, 1984) , cytokine expression (Tang et al., 1996; Martinez et al., 1996; Voice et al., 2001) , apoptosis (Delgado et al., 2002 ) and adhesion (Johnston et al., 1994; Xia et al., 1996; reviewed by Delgado et al., 2004 ).
An anatomical connection exists between the nervous and immune systems (Delgado et al., 2004) . Autonomic noradrenergic and cholinergic nerves of the peripheral nervous system innervate the thymus, spleen, lymph nodes and the mucosa-associated lymphoid tissues (MALT) of the pulmonary and gastrointestinal systems (Felten et al., 1987) . Immune cells that express VIP receptors in proximity to VIP positive nerve endings can respond to a ''neuro-delivered" biologically active ligand (Delgado et al., 1996; Goetzl et al., 1998; Cozzi, 1999) . VIP sources can also be non-neuronal as Th 2 , but not Th 1 , CD4 T cells synthesize and secrete VIP, acting in an autocrine or paracrine manner, to support the Th 2 immune response (Blum et al., 1992; Delgado and Ganea, 1999; Goetzl et al., 2001; Voice et al., 2001; Delgado and Ganea, 2001; Vassiliou et al., 2001) .
The immunomodulatory actions of this ''neuro-cytokine-like" ligand, VIP, on T cells has been demonstrated to act by suppressing the crucial T cell growth factor, IL-2, through a VPAC-1 signaling cAMP-dependent mechanism (Wang et al., 2000) . Therefore, VIP/ VPAC-1 signaling is thought to suppress bystander T cell activation (Lara-Marquez et al., 2001) . Upon receiving appropriate signals for activation, CD4 T cells decrease VPAC-1 mRNA steady-state levels P90% in mouse and human (Lara-Marquez et al., 2001; Voice et al., 2001 ) that facilitates optimal T cell activation. However, T cell regulatory mechanisms controlling the anti-inflammatory VPAC-1 GPCR are not well understood. 
